Trial Information
Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone
Inclusion Criteria:
- Diagnosis of low to intermediate risk prostate cancer and elected to have proton
radiation therapy at University of Florida Proton Therapy Institute (UFPTI).
Exclusion Criteria:
- Current use of Flomax, Hytrin, Cardura, Uroxatral, or Rapaflo.
- History of vasectomy.
- Current use of Lupron, Zoladex, Trelstar, Casodex, Eulexin.
- Current use of Avodart or Proscar.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Post treatment sperm count
Outcome Time Frame:
12 months after radiation therapy
Safety Issue:
No
Principal Investigator
Bradford S Hoppe, MD, MPH
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Florida Proton Therapy Institute
Authority:
United States: Institutional Review Board
Study ID:
UFPTI-0908-PR08
NCT ID:
NCT01072513
Start Date:
March 2010
Completion Date:
January 2018
Related Keywords:
- Prostate Cancer
- Semen Analysis, Prostate Cancer, Proton Radiation
- Prostatic Neoplasms
Name | Location |
University of Florida Proton Therapy Institute |
Jacksonville, Florida 32206 |